• Explore /
  • Poster
  • / Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology<em></em>.

Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology.

Abstract Poster

Authors

null

Radoslav Chekerov

NOGGO and Department of Gynecology, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany

Radoslav Chekerov , Peter Klare , Petra Krabisch , Jochem Potenberg , Georg Heinrich , Lothar Mueller , Christian M. Kurbacher , Eva-Maria Grischke , Elena Ioana Braicu , Pauline Wimberger , Jalid Sehouli

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01388621

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5558)

DOI

10.1200/JCO.2017.35.15_suppl.5558

Abstract #

5558

Poster Bd #

380

Abstract Disclosures

Similar Posters

Poster

2014 Gastrointestinal Cancers Symposium

A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.

A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.

First Author: Marcus Smith Noel

First Author: Karina Dahl Steffensen

First Author: Weijing Sun

First Author: I. Chau